Juan Berenguer, Pablo Ryan, Thomas Lutz, Luz Martín-Carbonero, Leire Pérez-Latorre, María J Vivancos, Jordi Navarro, Roser Navarro-Soler, Oscar L Ferrero, Rosario Palacios, Christoph Wyen, Pere Domingo, Malte B Monin, Xavier Camino, Marta Montero, Alexander Killer, Jakob J Malin, Ignacio De Los Santos, Stefan Esser, Luis E Morano, Ian López-Cruz, Jorge Valencia, Roger Vogelmann, Stefan Mauss, Antonio Rivero, Fauzi Elamouri, Carmen Hidalgo-Tenorio, Kathrin Van Bremen, Juncal Pérez-Somarriba, José Sanz, Daniel Beer, Axel Baumgarten, Annette Haberl, María J Galindo, María C Fariñas, Florian Voit, Nazifa Qurishi, Sebastian Noe, Sergio Reus, Pavel Khaykin, Stephan M Schneeweiss, Anders Boyd, Marta De Miguel, José M Bellón, Jürgen K Rockstroh
{"title":"Adherence to European AIDS clinical society hepatitis B management guidelines in people with HIV: real-world evidence from Spain and Germany.","authors":"Juan Berenguer, Pablo Ryan, Thomas Lutz, Luz Martín-Carbonero, Leire Pérez-Latorre, María J Vivancos, Jordi Navarro, Roser Navarro-Soler, Oscar L Ferrero, Rosario Palacios, Christoph Wyen, Pere Domingo, Malte B Monin, Xavier Camino, Marta Montero, Alexander Killer, Jakob J Malin, Ignacio De Los Santos, Stefan Esser, Luis E Morano, Ian López-Cruz, Jorge Valencia, Roger Vogelmann, Stefan Mauss, Antonio Rivero, Fauzi Elamouri, Carmen Hidalgo-Tenorio, Kathrin Van Bremen, Juncal Pérez-Somarriba, José Sanz, Daniel Beer, Axel Baumgarten, Annette Haberl, María J Galindo, María C Fariñas, Florian Voit, Nazifa Qurishi, Sebastian Noe, Sergio Reus, Pavel Khaykin, Stephan M Schneeweiss, Anders Boyd, Marta De Miguel, José M Bellón, Jürgen K Rockstroh","doi":"10.1097/QAD.0000000000004635","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate adherence to hepatitis B virus (HBV) management recommendations among people with HIV (PWH) and chronic HBV infection.</p><p><strong>Design: </strong>A multicenter cross-sectional study.</p><p><strong>Methods: </strong>We conducted a cross-sectional study in 42 centers in Spain and Germany between June 2024 and March 2025. Chronic HBV infection was defined as at least two positive hepatitis B surface antigen tests obtained more than 6 months apart. Adherence to 2023 European AIDS Clinical Society recommendations regarding anti-HBV treatment, liver enzyme monitoring, HBV-DNA testing, antihepatitis D virus (HDV) screening, and HDV-RNA confirmation was assessed. Hepatocellular carcinoma surveillance was evaluated separately and has been reported elsewhere.</p><p><strong>Results: </strong>A total of 1235 PWH with chronic HBV infection were included. The median age was 56 years, 84% were men, and 36% were born outside Europe. Overall, 88% had HIV-RNA less than 50 copies/ml, and the median CD4+ cell count was 623 cells/μl. Among participants with available HBV-DNA result, 87% had undetectable HBV-DNA. Guideline-recommended anti-HBV treatment was documented in 88% of individuals. During the previous 12 months, liver enzyme monitoring was performed in 94% and HBV-DNA testing in 71%. Overall, 81% had ever undergone anti-HDV testing and, among anti-HDV-positive individuals, 66% had undergone HDV-RNA testing.</p><p><strong>Conclusion: </strong>Although adherence to several components of HBV care was high, gaps remain in the implementation of current recommendations for PWH, particularly in HBV-DNA monitoring and HDV evaluation. Better integration of these measures into routine HIV care may improve long-term prevention of liver-related complications.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004635","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate adherence to hepatitis B virus (HBV) management recommendations among people with HIV (PWH) and chronic HBV infection.
Design: A multicenter cross-sectional study.
Methods: We conducted a cross-sectional study in 42 centers in Spain and Germany between June 2024 and March 2025. Chronic HBV infection was defined as at least two positive hepatitis B surface antigen tests obtained more than 6 months apart. Adherence to 2023 European AIDS Clinical Society recommendations regarding anti-HBV treatment, liver enzyme monitoring, HBV-DNA testing, antihepatitis D virus (HDV) screening, and HDV-RNA confirmation was assessed. Hepatocellular carcinoma surveillance was evaluated separately and has been reported elsewhere.
Results: A total of 1235 PWH with chronic HBV infection were included. The median age was 56 years, 84% were men, and 36% were born outside Europe. Overall, 88% had HIV-RNA less than 50 copies/ml, and the median CD4+ cell count was 623 cells/μl. Among participants with available HBV-DNA result, 87% had undetectable HBV-DNA. Guideline-recommended anti-HBV treatment was documented in 88% of individuals. During the previous 12 months, liver enzyme monitoring was performed in 94% and HBV-DNA testing in 71%. Overall, 81% had ever undergone anti-HDV testing and, among anti-HDV-positive individuals, 66% had undergone HDV-RNA testing.
Conclusion: Although adherence to several components of HBV care was high, gaps remain in the implementation of current recommendations for PWH, particularly in HBV-DNA monitoring and HDV evaluation. Better integration of these measures into routine HIV care may improve long-term prevention of liver-related complications.
期刊介绍：
Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
